RU2016101363A - Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью - Google Patents
Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью Download PDFInfo
- Publication number
- RU2016101363A RU2016101363A RU2016101363A RU2016101363A RU2016101363A RU 2016101363 A RU2016101363 A RU 2016101363A RU 2016101363 A RU2016101363 A RU 2016101363A RU 2016101363 A RU2016101363 A RU 2016101363A RU 2016101363 A RU2016101363 A RU 2016101363A
- Authority
- RU
- Russia
- Prior art keywords
- derivatives
- refractory
- metabolites
- pharmaceutical composition
- glucocorticoid
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 title claims 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 23
- 201000010099 disease Diseases 0.000 title claims 17
- 238000000034 method Methods 0.000 title claims 9
- 239000002207 metabolite Substances 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 239000003246 corticosteroid Substances 0.000 claims 25
- 239000000583 progesterone congener Substances 0.000 claims 12
- 208000011580 syndromic disease Diseases 0.000 claims 12
- 229960001334 corticosteroids Drugs 0.000 claims 9
- 239000003270 steroid hormone Substances 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 208000006673 asthma Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 201000011152 Pemphigus Diseases 0.000 claims 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 5
- -1 amine salt Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000001747 exhibiting effect Effects 0.000 claims 5
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 5
- 206010003645 Atopy Diseases 0.000 claims 4
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 claims 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 4
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims 3
- 208000017194 Affective disease Diseases 0.000 claims 3
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000000112 Myalgia Diseases 0.000 claims 3
- 241000721454 Pemphigus Species 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- GTFUITFQDGVJSK-XGXHKTLJSA-N gestonorone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 GTFUITFQDGVJSK-XGXHKTLJSA-N 0.000 claims 3
- 229960004400 levonorgestrel Drugs 0.000 claims 3
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims 3
- 230000027758 ovulation cycle Effects 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 206010001367 Adrenal insufficiency Diseases 0.000 claims 2
- 206010067484 Adverse reaction Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000037157 Azotemia Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000028399 Critical Illness Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000014311 Cushing syndrome Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 206010061822 Drug intolerance Diseases 0.000 claims 2
- 208000018137 Extraocular muscle disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018691 Granuloma Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 2
- 208000011200 Kawasaki disease Diseases 0.000 claims 2
- 229940122696 MAP kinase inhibitor Drugs 0.000 claims 2
- 206010027259 Meningitis tuberculous Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001388 Opportunistic Infections Diseases 0.000 claims 2
- 208000004931 Orbital Myositis Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 241001303601 Rosacea Species 0.000 claims 2
- 206010070834 Sensitisation Diseases 0.000 claims 2
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 206010043784 Thyroiditis subacute Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010044608 Trichiniasis Diseases 0.000 claims 2
- 208000022971 Tuberculous meningitis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 229930003316 Vitamin D Natural products 0.000 claims 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 229940022663 acetate Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 206010001053 acute respiratory failure Diseases 0.000 claims 2
- 239000003470 adrenal cortex hormone Substances 0.000 claims 2
- 201000005255 adrenal gland hyperfunction Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000006838 adverse reaction Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000006752 brain edema Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229960003843 cyproterone Drugs 0.000 claims 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000009803 desquamative interstitial pneumonia Diseases 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 229960003309 dienogest Drugs 0.000 claims 2
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- 229960004845 drospirenone Drugs 0.000 claims 2
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
- 229960000218 etynodiol Drugs 0.000 claims 2
- 229940084434 fungoid Drugs 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 claims 2
- 208000018022 idiopathic eosinophilic pneumonia Diseases 0.000 claims 2
- 230000036737 immune function Effects 0.000 claims 2
- 230000000495 immunoinflammatory effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 230000013016 learning Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 208000001223 meningeal tuberculosis Diseases 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 229960004911 nomegestrol Drugs 0.000 claims 2
- 229940053934 norethindrone Drugs 0.000 claims 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims 2
- 229960001858 norethynodrel Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 201000010668 orbital plasma cell granuloma Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000037081 physical activity Effects 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 229960002847 prasterone Drugs 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 229960003387 progesterone Drugs 0.000 claims 2
- 239000000186 progesterone Substances 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 230000002829 reductive effect Effects 0.000 claims 2
- 201000004193 respiratory failure Diseases 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 230000000552 rheumatic effect Effects 0.000 claims 2
- 201000003068 rheumatic fever Diseases 0.000 claims 2
- 201000004700 rosacea Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000008313 sensitization Effects 0.000 claims 2
- 206010040400 serum sickness Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 201000007497 subacute thyroiditis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 229960000278 theophylline Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000003982 trichinellosis Diseases 0.000 claims 2
- 201000007588 trichinosis Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000009852 uremia Diseases 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 235000019166 vitamin D Nutrition 0.000 claims 2
- 239000011710 vitamin D Substances 0.000 claims 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 2
- 229940046008 vitamin d Drugs 0.000 claims 2
- RJKFOVLPORLFTN-HQZYFCCVSA-N (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-HQZYFCCVSA-N 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
- NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims 1
- 150000000318 19-norprogesterones Chemical class 0.000 claims 1
- 150000000319 19-nortestosterones Chemical class 0.000 claims 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 claims 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 229940049937 Pgp inhibitor Drugs 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 206010036030 Polyarthritis Diseases 0.000 claims 1
- 208000012287 Prolapse Diseases 0.000 claims 1
- 208000021329 Refractory celiac disease Diseases 0.000 claims 1
- 241000606651 Rickettsiales Species 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 150000001733 carboxylic acid esters Chemical class 0.000 claims 1
- 229960003996 chlormadinone Drugs 0.000 claims 1
- 229960001616 chlormadinone acetate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003290 cortisone acetate Drugs 0.000 claims 1
- 229960000978 cyproterone acetate Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960001853 demegestone Drugs 0.000 claims 1
- JWAHBTQSSMYISL-MHTWAQMVSA-N demegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 JWAHBTQSSMYISL-MHTWAQMVSA-N 0.000 claims 1
- 229960004976 desogestrel Drugs 0.000 claims 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960004913 dydrogesterone Drugs 0.000 claims 1
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims 1
- CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 claims 1
- 229950007611 elcometrine Drugs 0.000 claims 1
- 150000002085 enols Chemical class 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960005309 estradiol Drugs 0.000 claims 1
- 229930182833 estradiol Natural products 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960002941 etonogestrel Drugs 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 229960000618 fluprednisolone Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960003812 gestonorone caproate Drugs 0.000 claims 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 229940076085 gold Drugs 0.000 claims 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000003832 immune regulation Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229960001910 lynestrenol Drugs 0.000 claims 1
- 229960000606 medrogestone Drugs 0.000 claims 1
- HCFSGRMEEXUOSS-JXEXPEPMSA-N medrogestone Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(C)[C@@]1(C)CC2 HCFSGRMEEXUOSS-JXEXPEPMSA-N 0.000 claims 1
- 229960004616 medroxyprogesterone Drugs 0.000 claims 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 1
- 229960004719 nandrolone Drugs 0.000 claims 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- ISHXLNHNDMZNMC-XUDSTZEESA-N norelgestromin Chemical compound ON=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ISHXLNHNDMZNMC-XUDSTZEESA-N 0.000 claims 1
- 229960000417 norgestimate Drugs 0.000 claims 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims 1
- 230000036961 partial effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000030428 polyarticular arthritis Diseases 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003145 progesterone derivatives Chemical class 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 229960001584 promegestone Drugs 0.000 claims 1
- QFFCYTLOTYIJMR-XMGTWHOFSA-N promegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)CC)(C)[C@@]1(C)CC2 QFFCYTLOTYIJMR-XMGTWHOFSA-N 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical class C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 claims 1
- 229960001023 tibolone Drugs 0.000 claims 1
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims 1
- 229950008546 trimegestone Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30232510P | 2010-02-08 | 2010-02-08 | |
| US61/302,325 | 2010-02-08 | ||
| US13/021,950 US10231976B2 (en) | 2010-02-08 | 2011-02-07 | Methods for the use of progestogen as a glucocorticoid sensitizer |
| US13/021,950 | 2011-02-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012135985/15A Division RU2575824C2 (ru) | 2010-02-08 | 2011-02-07 | Способы применения прогестогена в качестве глюкокортикоидного сенсибилизатора |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016101363A3 RU2016101363A3 (enExample) | 2018-11-21 |
| RU2016101363A true RU2016101363A (ru) | 2018-11-21 |
Family
ID=44353892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016101363A RU2016101363A (ru) | 2010-02-08 | 2011-02-07 | Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10231976B2 (enExample) |
| EP (2) | EP2533799B8 (enExample) |
| JP (1) | JP5913136B2 (enExample) |
| CN (1) | CN102811730B (enExample) |
| BR (1) | BR112012019725A2 (enExample) |
| ES (1) | ES2773079T3 (enExample) |
| RU (1) | RU2016101363A (enExample) |
| WO (1) | WO2011097571A2 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10987361B2 (en) * | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| US20110262502A1 (en) * | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| US10993879B2 (en) * | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| RU2016101363A (ru) | 2010-02-08 | 2018-11-21 | Прэари Фармасьютикалз, Ллк | Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US20160008376A1 (en) * | 2014-07-10 | 2016-01-14 | Biocopea Limited | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders |
| US9624998B2 (en) | 2014-07-30 | 2017-04-18 | Tenneco Automotive Operating Company Inc. | Electromagnetic flywheel damper and method therefor |
| BR112017004163A2 (pt) * | 2014-09-03 | 2017-12-05 | Rhizen Pharmaceuticals Sa | método de tratamento e composições com um inibidor de quinase pi3k delta e gamma duplo e um corticostoide |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CN108367012B (zh) * | 2015-09-21 | 2021-12-24 | 深圳埃格林医药有限公司 | 自体免疫性和自身炎症性疾病的治疗 |
| CN106994128A (zh) * | 2016-01-26 | 2017-08-01 | 上海普瑞得生物技术有限公司 | 17-α羟孕酮化合物在预防和治疗中性粒细胞炎症疾病中的应用 |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CN106310280A (zh) * | 2016-08-18 | 2017-01-11 | 滨州医学院 | 地瑞那韦增强糖皮质激素抗炎作用的医药新用途 |
| EP3548035A4 (en) * | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| CN110573154A (zh) | 2017-02-06 | 2019-12-13 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| CN108159057A (zh) * | 2018-02-09 | 2018-06-15 | 上海礼璞生物医药科技有限公司 | 黄体酮及其药学上可接受的衍生物在制备抑制α平滑肌肌动蛋白表达的药物中的用途 |
| CN108159056A (zh) * | 2018-02-09 | 2018-06-15 | 上海礼璞生物医药科技有限公司 | 孕激素在制备组蛋白去乙酰化酶抑制剂和气道周围胶原沉积抑制剂药物中的应用及抑制剂 |
| CN108272804A (zh) * | 2018-02-09 | 2018-07-13 | 上海礼璞生物医药科技有限公司 | 孕激素在制备糖原合成酶激酶-3β抑制剂药物中的应用及糖原合成酶激酶-3β抑制剂 |
| EA202191422A1 (ru) | 2018-11-21 | 2021-10-21 | Кейс Вестерн Ризерв Юниверсити | Композиции и способы модулирования активности короткоцепочечной дегидрогеназы |
| KR102490714B1 (ko) * | 2018-12-28 | 2023-01-26 | 재단법인 아산사회복지재단 | Pibf 단백질을 유효성분으로 함유하는 염증성 질환 예방 또는 치료용 약학 조성물 |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| CN113559107B (zh) * | 2020-04-28 | 2023-01-06 | 深圳埃格林医药有限公司 | 孕激素在制备抑制细胞因子风暴的药物中的应用 |
| CN113616660A (zh) * | 2020-05-07 | 2021-11-09 | 深圳埃格林医药有限公司 | 孕激素制剂及其用途 |
| CN114569623A (zh) * | 2020-12-01 | 2022-06-03 | 深圳埃格林医药有限公司 | 己酸羟孕酮在制备治疗间质性肺炎的药物中的用途 |
| EP4209219A1 (en) * | 2022-01-07 | 2023-07-12 | MetrioPharm AG | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione |
| CN115501236B (zh) * | 2022-11-09 | 2024-01-23 | 复旦大学附属肿瘤医院 | 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用 |
| CN118924767B (zh) * | 2024-07-25 | 2025-11-11 | 中南大学湘雅医院 | 孕烯醇酮作为活性成分在制备银屑病或特应性皮炎的治疗药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559332A (en) * | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
| US4720489A (en) * | 1984-10-15 | 1988-01-19 | Douglas Shander | Hair growth modification with ornithine decarboxylase inhibitors |
| AU763307B2 (en) * | 1998-02-04 | 2003-07-17 | Charlotte-Mecklenburg Hospital Authority | Androsterone derivatives for inhibiting DNA binding of AP-1 and airway smooth muscle proliferation |
| US6562370B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| US20010034340A1 (en) * | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
| ATE307591T1 (de) * | 2000-12-14 | 2005-11-15 | Ortho Mcneil Pharm Inc | Zubereitungen enthaltend ein steroidhormon und ein stabilisierungsmittel in nicht-kristalliner form |
| FR2821555B1 (fr) * | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
| WO2003049791A1 (en) | 2001-12-05 | 2003-06-19 | Nupharmx, Llc | Medical device and method for inhalation of aerosolized drug with heliox |
| JP2005523915A (ja) * | 2002-04-26 | 2005-08-11 | ファイザー ヘルス アーベー | 代謝性症候群の処置 |
| AU2003278918A1 (en) * | 2002-09-23 | 2004-04-08 | The General Hospital Coporation | Methods for diagnosing and treating tumors and suppressing cd promoters |
| DE10251028A1 (de) * | 2002-11-01 | 2004-05-19 | Jenapharm Gmbh & Co. Kg | Verwendung von Progesteron oder einem Progesteronrezeptor-Agonisten zur Hemmung der Steroidsynthese |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| US7833545B2 (en) * | 2003-04-29 | 2010-11-16 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
| US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| MXPA06012088A (es) | 2004-04-22 | 2007-08-14 | Duocort Ab | Composiciones farmaceuticas para terapia aguda con glucocorticoides. |
| US20060052306A1 (en) | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| EP1773344A1 (en) * | 2004-07-07 | 2007-04-18 | Wyeth a Corporation of the State of Delaware | Cyclic progestin regimens and kits |
| GB0425266D0 (en) | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
| PL1868614T3 (pl) | 2005-03-24 | 2013-01-31 | Univ Emory | Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem |
| ATE543489T1 (de) * | 2005-05-26 | 2012-02-15 | Teva Womens Health Inc | Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
| EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| US20110262502A1 (en) | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| US10987361B2 (en) | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| RU2016101363A (ru) | 2010-02-08 | 2018-11-21 | Прэари Фармасьютикалз, Ллк | Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью |
| PT105058B (pt) | 2010-04-21 | 2013-04-17 | Hovione Farmaciencia S A | Processo para processamento de partículas de ingredientes activos farmacêuticos |
-
2011
- 2011-02-07 RU RU2016101363A patent/RU2016101363A/ru unknown
- 2011-02-07 WO PCT/US2011/023917 patent/WO2011097571A2/en not_active Ceased
- 2011-02-07 ES ES11740491T patent/ES2773079T3/es active Active
- 2011-02-07 JP JP2012552135A patent/JP5913136B2/ja active Active
- 2011-02-07 CN CN201180005214.2A patent/CN102811730B/zh active Active
- 2011-02-07 EP EP11740491.3A patent/EP2533799B8/en active Active
- 2011-02-07 BR BR112012019725-8A patent/BR112012019725A2/pt not_active Application Discontinuation
- 2011-02-07 EP EP19209932.3A patent/EP3689364A1/en not_active Withdrawn
- 2011-02-07 US US13/021,950 patent/US10231976B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2533799A2 (en) | 2012-12-19 |
| EP2533799B8 (en) | 2019-12-25 |
| BR112012019725A2 (pt) | 2020-11-10 |
| JP5913136B2 (ja) | 2016-04-27 |
| WO2011097571A2 (en) | 2011-08-11 |
| US10231976B2 (en) | 2019-03-19 |
| US20110195031A1 (en) | 2011-08-11 |
| CN102811730B (zh) | 2014-07-09 |
| RU2012135985A (ru) | 2014-03-20 |
| RU2016101363A3 (enExample) | 2018-11-21 |
| ES2773079T3 (es) | 2020-07-09 |
| EP3689364A1 (en) | 2020-08-05 |
| WO2011097571A3 (en) | 2011-12-29 |
| EP2533799B1 (en) | 2019-11-20 |
| EP2533799A4 (en) | 2013-07-31 |
| JP2013518908A (ja) | 2013-05-23 |
| CN102811730A (zh) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016101363A (ru) | Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью | |
| CN103582484B (zh) | 17-己酸羟孕酮(17-hpc)的肺部递送 | |
| JP2013518908A5 (enExample) | ||
| Rasheed et al. | A review of natural steroids and their applications | |
| JP2020502070A5 (enExample) | ||
| Patil et al. | Update in the management of extraintestinal manifestations of inflammatory bowel disease | |
| CN117017998A (zh) | 用于降低类固醇剂量并治疗炎性和自身免疫性疾病的大麻二酚 | |
| EP2731596A2 (de) | Kombinationstherapeutikum | |
| US20120245552A1 (en) | Combination Therapy | |
| CN103298343A (zh) | 类固醇和糖皮质激素受体拮抗剂组合疗法 | |
| JP2001508034A (ja) | 鼻ポリープの治療におけるｈ▲上＋▼，ｋ▲上＋▼―ａｔｐアーゼ阻害剤の使用 | |
| US20210361674A1 (en) | Treating Auto-Immune and Auto-Inflammatory Diseases | |
| Singh et al. | Revisiting the role of steroidal therapeutics in the 21st century: an update on FDA approved steroidal drugs (2000–2024) | |
| Abshagen et al. | Influence of spironolactone on endogenous steroid metabolism in man | |
| EP2026818B1 (en) | Combination of steroids having transporter-enhanced corticosteroid activity | |
| HRP20200968T1 (hr) | Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid | |
| IL312514A (en) | Corticosteroid reduction in treatment with anti-CD38 antibodies | |
| US3231468A (en) | Dexamethasone-cyproheptadine oral antiflammatory compositions | |
| RU2575824C2 (ru) | Способы применения прогестогена в качестве глюкокортикоидного сенсибилизатора | |
| HK40038111A (en) | Methods for the use of progestogen as a glucocorticoid sensitizer | |
| Bissell et al. | Glucocorticoids | |
| Bielory | In search of the perfect steroid | |
| Matos et al. | Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids | |
| RU2021113995A (ru) | Способы введения кортикостероидов | |
| Van Rensburg | A guide to prescribing corticosteroids |